Programme

Social Activities

Co-organiser: Vivlion Meeting point: outside conference venue main entrance (Øksnehallen)

Scientific Sessions

Chairpersons: Eric Kmiec (Gene-Editing Institute at ChristianaCare and CorriXR Therapeutics, United States) and Ayal Hendel (Bar-Ilan University, Israel)

Breaks

Panel Discussions

Moderator and co-organiser: Daniël Warmerdam, UMC Amsterdam Panelists: Alvin Luk (HuidaGene Therapeutics), Patient advocate Jimi Olaghere, Cecilia Jimenez-Mallebrera (Institut de Recerca Sant Joan de Déu. Hospital Sant Joan de Déu Barcelona and CIBERER), Liselotte Wesley Andersen (Rare Diseases Denmark), Kevin Holden (Synthego) Innovative CRISPR-based therapies hold tremendous promise for addressing a range of diseases, including rare disorders and diseases with unmet medical needs. However, ensuring equitable patient access remains a significant challenge. This one-hour panel discussion will examine key issues involved in the availability and accessibility of CRISPR-based medicines. By bringing together diverse stakeholders, the discussion aims to provide a comprehensive perspective on overcoming barriers to access and ensuring these transformative therapies reach those who need them most. Audience participation is highly encouraged.

Scientific Sessions

Chairpersons: Marcello Maresca (AstraZeneca, Sweden) and Karim Benabdellah (GENyO Pfizer-University Granada and GeneHumdi Action Chair, Spain)

Breaks

A Coffee Tuc Tuc sponsored by Lonza will be available from 12:30-14:30 at their booth A-4.

Scientific Sessions

Chairpersons: Carla Fuster (University of Freiburg, Germany) and Jan Gorodkin (University of Copenhagen, Denmark)

Panel Discussions

Moderator: Gorm Palmgren, CRISPR Medicine News, Denmark Panelists: Attila Sebe (Paul-Ehrlich-Institute), Özcan Met (Cell Therapy Unit CCIT-DK and DTU HealthTech, Denmark), Eric B. Kmiec, Gene-Editing Institute at ChristianaCare and CorriXR Therapeutics (United States) As CRISPR-based therapies advance towards clinical application, navigating the complex regulatory landscape remains a critical challenge. This panel discussion will explore the evolving framework for gene-editing therapies, focusing on regulatory hurdles, lessons learned from recent approvals, and the path forward for ensuring patient safety and access. Experts from regulatory bodies, research institutions, and industry will share insights on how regulatory strategies can support innovation while maintaining rigorous safety and efficacy standards. Audience participation is encouraged to foster a dynamic and informative discussion.

Breaks

Scientific Sessions

Chairpersons: Rasmus Bak (Aarhus University, Denmark) and Ayal Hendel (Bar-Ilan University, Israel)

Social Activities

An evening of fun and games with food and beverages!